Liquidia (LQDA) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precigen (PGEN) has outperformed Liquidia (LQDA) over the past year, gaining 136.0% versus a gain of 16.4%. Over five years, LQDA leads with a +775.6% price change compared with +63.4% for PGEN. Precigen is the larger company by market cap ($2.72 billion vs $2.51 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LQDA | PGEN |
|---|---|---|
| Share price | $28.02 | $7.60 |
| Market cap | $2.51B | $2.72B |
| 1-day change | +5.02% | +0.80% |
| YTD return | -18.76% | +81.82% |
| 1-year return | +16.36% | +136.02% |
| 5-year return | +775.63% | +63.44% |
| P/E ratio (TTM) | 19.19 | — |
| Forward P/E | 11.66 | — |
| EPS (TTM) | $1.46 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | +146.73% |
| Net income (latest FY) | — | $-250.64M |
| Operating margin | — | -1141.13% |
| Net margin | — | -2588.21% |
| 52-week high | $93.61 | $8.98 |
| 52-week low | $21.94 | $2.99 |
| Distance from 52-week high | -70.07% | -15.37% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +77.27% | +79.61% |
| Average volume | 2.40M | 5.03M |
| Shares outstanding | 89.51M | 358.04M |
| Employees | 216 | 160 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed LQDA by 119.7 percentage points over the past year.
- The two companies sit in different sectors: Liquidia in Health Care and Precigen in Healthcare.
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Healthcare · Biotechnology · 160 employees
LQDA vs PGEN FAQ
Which is bigger, Liquidia or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $2.72B compared with $2.51B for Liquidia (LQDA).
Which stock has performed better over the past year, LQDA or PGEN?
PGEN returned +136.02% over the past 12 months, compared with +16.36% for LQDA (price return, excluding dividends). Past performance does not predict future results.
Are Liquidia and Precigen in the same industry?
No. Liquidia is in the Health Care sector, while Precigen is in Healthcare.